{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T01:50:26Z","timestamp":1769565026451,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00108-025-02039-4","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:57:39Z","timestamp":1768813059000},"page":"181-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positiver Interferon-\u03b3-release-Assay und Immunsuppression\u00a0\u2013 leitliniengerechtes Management der Tuberkuloseinfektion","Positive interferon-gamma release assay and immunosuppression: guideline-based diagnosis and treatment of tuberculosis infection"],"prefix":"10.1007","volume":"67","author":[{"given":"Carola","family":"Horn-Magar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Steinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rybniker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2039_CR1","unstructured":"World Health Organization (2024) WHO consolidated guidelines on tuberculosis. Module\u00a01, Prevention : tuberculosis preventive treatment"},{"issue":"11","key":"2039_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1055\/a-2148-7769","volume":"85","author":"R Diel","year":"2023","unstructured":"Diel\u00a0R, Breuer\u00a0C, B\u00f6s\u00a0L, Geerdes-Fenge\u00a0H, G\u00fcnther\u00a0A, H\u00e4cker\u00a0B, Hannemann\u00a0J, Nienhaus\u00a0A, Priwitzer\u00a0M, Witte\u00a0P, Bauer\u00a0T (2023) Empfehlungen f\u00fcr die Umgebungsuntersuchungen bei Tuberkulose \u2013 Update 2023. Gesundheitswesen 85(11):1076\u20131098","journal-title":"Gesundheitswesen"},{"issue":"12","key":"2039_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1055\/a-2172-9575","volume":"77","author":"P Witte","year":"2023","unstructured":"Witte\u00a0P, Arvand\u00a0M, Barth\u00a0S, Diel\u00a0R, Friesen\u00a0I, Gastmeier\u00a0P, H\u00e4cker\u00a0B, Hauer\u00a0B, Kuhns\u00a0M, Nienhaus\u00a0A, Otto-Knapp\u00a0R, Richter\u00a0E, Wischnewski\u00a0N, Ziegler\u00a0R, Bauer\u00a0T (2023) Infektionspr\u00e4vention & Hygiene bei Tuberkulose \u2013 Empfehlungen des DZK. Pneumologie 77(12):983\u20131000","journal-title":"Pneumologie"},{"issue":"8","key":"2039_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMra1200894","volume":"368","author":"A Zumla","year":"2013","unstructured":"Zumla\u00a0A, Raviglione\u00a0M, Hafner\u00a0R, von Reyn\u00a0CF (2013) Tuberculosis. N\u00a0Engl J Med 368(8):745\u2013755","journal-title":"N Engl J Med"},{"issue":"10181","key":"2039_CR5","first-page":"1642","volume":"393","author":"J Furin","year":"2019","unstructured":"Furin\u00a0J, Cox\u00a0H, Pai\u00a0M (2019) Lancet 20. Tuberculosis 393(10181):1642\u20131656","journal-title":"Tuberculosis"},{"key":"2039_CR6","first-page":"1","volume":"19","author":"I Sutherland","year":"1976","unstructured":"Sutherland\u00a0I (1976) Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 19:1\u201363","journal-title":"Adv Tuberc Res"},{"issue":"1","key":"2039_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/ajrccm.153.1.8542139","volume":"153","author":"AL Kritski","year":"1996","unstructured":"Kritski\u00a0AL, Marques\u00a0MJ, Rabahi\u00a0MF, Vieira\u00a0MA, Werneck-Barroso\u00a0E, Carvalho\u00a0CE, Andrade Gde\u00a0N, Bravo-de-Souza\u00a0R, Andrade\u00a0LM, Gontijo\u00a0PP, Riley\u00a0LW (1996) Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 153(1):331\u2013335","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2039_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/aje\/kwt246","volume":"179","author":"KM Shea","year":"2014","unstructured":"Shea\u00a0KM, Kammerer\u00a0JS, Winston\u00a0CA, Navin\u00a0TR, Horsburgh\u00a0CR Jr (2014) Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 179(2):216\u2013225","journal-title":"Am J Epidemiol"},{"issue":"11","key":"2039_CR9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/a-1934-8303","volume":"76","author":"T Schaberg","year":"2022","unstructured":"Schaberg\u00a0T, Brinkmann\u00a0F, Feiterna-Sperling\u00a0C, Geerdes-Fenge\u00a0H, Hartmann\u00a0P, H\u00e4cker\u00a0B, Hauer\u00a0B, Haas\u00a0W, Heyckendorf\u00a0J, Lange\u00a0C, Maurer\u00a0FP, Nienhaus\u00a0A, Otto-Knapp\u00a0R, Priwitzer\u00a0M, Richter\u00a0E, Salzer\u00a0HJF, Schoch\u00a0O, Sch\u00f6nfeld\u00a0N, Stahlmann\u00a0R, Bauer\u00a0T (2022) S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 76(11):727\u2013819","journal-title":"Pneumologie"},{"issue":"10","key":"2039_CR10","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben\u00a0RM, Dodd\u00a0PJ (2016) The Global Burden of Latent Tuberculosis Infection: A\u00a0Re-estimation Using Mathematical Modelling. PLoS Med 13(10):e1002152","journal-title":"PLoS Med"},{"issue":"10","key":"2039_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2334-10-107","volume":"30","author":"A Schablon","year":"2010","unstructured":"Schablon\u00a0A, Harling\u00a0M, Diel\u00a0R, Nienhaus\u00a0A (2010) Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a\u00a0multicentre prevalence study. BMC Infect Dis 30(10):107","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2039_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/ijerph15061263","volume":"15","author":"A Jablonka","year":"2018","unstructured":"Jablonka\u00a0A, Dopfer\u00a0C, Happle\u00a0C, Sogkas\u00a0G, Ernst\u00a0D, Atschekzei\u00a0F, Hirsch\u00a0S, Sch\u00e4ll\u00a0A, Jirmo\u00a0A, Solbach\u00a0P, Schmidt\u00a0RE, Behrens\u00a0GMN, Wetzke\u00a0M (2018) Tuberculosis Specific Interferon-Gamma Production in a\u00a0Current Refugee Cohort in Western Europe. Int J Environ Res Public Health 15(6):1263","journal-title":"Int J Environ Res Public Health"},{"key":"2039_CR13","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization (2025) Global tuberculosis report 2025. Geneva"},{"issue":"10","key":"2039_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","volume":"177","author":"R Diel","year":"2008","unstructured":"Diel\u00a0R, Loddenkemper\u00a0R, Meywald-Walter\u00a0K, Niemann\u00a0S, Nienhaus\u00a0A (2008) Predictive value of a\u00a0whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177(10):1164\u20131170","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2039_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","volume":"12","author":"CK Lee","year":"2018","unstructured":"Lee\u00a0CK, Wong\u00a0SHV, Lui\u00a0G, Tang\u00a0W, Tam\u00a0LS, Ip\u00a0M, Hung\u00a0E, Chen\u00a0M, Wu\u00a0JC, Ng\u00a0SC (2018) A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. J\u00a0Crohns Colitis 12(8):954\u2013962","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2039_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00393-022-01274-6","volume":"82","author":"E Rath","year":"2023","unstructured":"Rath\u00a0E, Bonelli\u00a0M, Duftner\u00a0C, Gruber\u00a0J, Mandl\u00a0P, Moazedi-Furst\u00a0F, Pieringer\u00a0H, Puchner\u00a0R, Flick\u00a0H, Salzer\u00a0HJF, Weiss\u00a0G, Winkler\u00a0S, Skvara\u00a0H, Moschen\u00a0A, Hofer\u00a0H, Feurstein\u00a0J, Sautner\u00a0J (2023) Consensus Statement der \u00d6sterreichischen Gesellschaften f\u00fcr Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder \u201etargeted synthetic\u201c DMARDs (\u201cdisease modifying antirheumatic drugs\u201d). Z\u00a0Rheumatol 82(2):163\u2013174","journal-title":"Z Rheumatol"},{"key":"2039_CR17","doi-asserted-by":"crossref","unstructured":"Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F (2018) Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther: 501\u2013512","DOI":"10.1080\/14787210.2018.1483238"},{"issue":"4","key":"2039_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1055\/a-1294-1580","volume":"75","author":"R Diel","year":"2021","unstructured":"Diel\u00a0R, Schaberg\u00a0T, Nienhaus\u00a0A, Otto-Knapp\u00a0R, Kneitz\u00a0C, Krause\u00a0A, Fabri\u00a0M, Mrowietz\u00a0U, Bauer\u00a0T, H\u00e4cker\u00a0B (2021) Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie 75(4):293\u2013303","journal-title":"Pneumologie"},{"issue":"11","key":"2039_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1159\/000547109","volume":"104","author":"Y Park","year":"2025","unstructured":"Park\u00a0Y, Min\u00a0J, Lim\u00a0JU, Yeo\u00a0CD, Kang\u00a0HS, Choi\u00a0JY, Kim\u00a0KY, Kim\u00a0SH, Park\u00a0JW (2025) Increased Risk of Tuberculosis Disease in Lung Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A\u00a0Retrospective Multicenter Study. Respiration 104(11):847\u2013857","journal-title":"Respiration"},{"issue":"11","key":"2039_CR20","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00262-021-02905-8","volume":"70","author":"GR Stroh","year":"2021","unstructured":"Stroh\u00a0GR, Peikert\u00a0T, Escalante\u00a0P (2021) Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a\u00a0non-endemic tuberculosis area. Cancer Immunol Immunother 70(11):3105\u20133111","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2039_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis\u00a0GE, Nikiphorou\u00a0E, Dey\u00a0M, Zhao\u00a0SS, Courvoisier\u00a0DS, Arnaud\u00a0L, Atzeni\u00a0F, Behrens\u00a0GM, Bijlsma\u00a0JW, B\u00f6hm\u00a0P, Constantinou\u00a0CA, Garcia-Diaz\u00a0S, Kapetanovic\u00a0MC, Lauper\u00a0K, Lu\u00eds\u00a0M, Morel\u00a0J, Nagy\u00a0G, Polverino\u00a0E, van Rompay\u00a0J, Sebastiani\u00a0M, Strangfeld\u00a0A, de Thurah\u00a0A, Galloway\u00a0J, Hyrich\u00a0KL (2023) EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 82(6):742\u2013753","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2039_CR22","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1183\/13993003.01047-2015","volume":"46","author":"M Sester","year":"2015","unstructured":"Sester\u00a0M, van Crevel\u00a0R, Leth Fv, Lange\u00a0C (2015) Numbers needed to treat to prevent tuberculosis. Eur Respir\u00a0J 46(6):1836\u20131838","journal-title":"Eur Respir J"},{"issue":"2","key":"2039_CR23","first-page":"CD001363","volume":"1999","author":"MJ Smieja","year":"1999","unstructured":"Smieja\u00a0MJ, Marchetti\u00a0CA, Cook\u00a0DJ, Smaill\u00a0FM (1999) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999(2):CD1363","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2039_CR24","first-page":"CD000171","volume":"2010","author":"C Akolo","year":"2010","unstructured":"Akolo\u00a0C, Adetifa\u00a0I, Shepperd\u00a0S, Volmink\u00a0J (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010(1):CD171","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2039_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling\u00a0TR, Njie\u00a0G, Zenner\u00a0D, Cohn\u00a0DL, Reves\u00a0R, Ahmed\u00a0A, Menzies\u00a0D, Horsburgh\u00a0CR Jr, Crane\u00a0CM, Burgos\u00a0M, LoBue\u00a0P, Winston\u00a0CA, Belknap\u00a0R (2020) Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 69(1):1\u201311","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2039_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies\u00a0D, Adjobimey\u00a0M, Ruslami\u00a0R, Trajman\u00a0A, Sow\u00a0O, Kim\u00a0H, Obeng Baah\u00a0J, Marks\u00a0GB, Long\u00a0R, Hoeppner\u00a0V, Elwood\u00a0K, Al-Jahdali\u00a0H, Gninafon\u00a0M, Apriani\u00a0L, Koesoemadinata\u00a0RC, Kritski\u00a0A, Rolla\u00a0V, Bah\u00a0B, Camara\u00a0A, Boakye\u00a0I, Cook\u00a0VJ, Goldberg\u00a0H, Valiquette\u00a0C, Hornby\u00a0K, Dion\u00a0MJ, Li\u00a0PZ, Hill\u00a0PC, Schwartzman\u00a0K, Benedetti\u00a0A (2018) Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N\u00a0Engl J Med 379(5):440\u2013453","journal-title":"N Engl J Med"},{"issue":"9","key":"2039_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","volume":"190","author":"R Sloot","year":"2014","unstructured":"Sloot\u00a0R, Schim van der Loeff\u00a0MF, Kouw\u00a0PM, Borgdorff\u00a0MW (2014) Risk of tuberculosis after recent exposure. A\u00a010-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 190(9):1044\u20131052","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02039-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:01:17Z","timestamp":1769522477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02039-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2039"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02039-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"8 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"I.\u00a0Su\u00e1rez\n                      : A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Deutsches Zentrum f\u00fcr Infektionsforschung.\u00a0\u2013 Honorar: Diasorin, Biomerieux, ViiV.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte: Fach\u00e4rztin f\u00fcr Innere Medizin und Infektiologie, Uniklinik K\u00f6ln, Medizinische Klinik\u00a0I, Ober\u00e4rztin; Institutsleiter: Prof. M. Hallek | Mitgliedschaften: DGI, DGIM, Deutscher \u00c4rztinnenbund.\n                      C. Horn-Magar\n                      : A. Finanzielle Interessen: C. Horn-Magar gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Fach\u00e4rztin f\u00fcr Innere Medizin, Klinik\u00a0I f\u00fcr Innere Medizin, Uniklinik K\u00f6ln | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin, Deutsche Gesellschaft f\u00fcr Infektiologie, Deutsche Gesellschaft f\u00fcr Tropenmedizin, Reisemedizin und Globale Gesundheit e.\u202fV.\n                      J. Steinke\n                      : A. Finanzielle Interessen: J. Steinke gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter Assistenzarzt in der Weiterbildung, Uniklinik K\u00f6ln, Klinik I f\u00fcr Innere Medizin; Institutsleiter: Prof. Dr. Michael Hallek | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Infektiologie (DGI), Deutsche Gesellschaft f\u00fcr Tropenmedizin, Reisemedizin und globale Gesundheit (DTG), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM) | Sektionssprecher der jungen DGI der Deutschen Gesellschaft f\u00fcr Infektiologie (DGI).\n                      P. K\u00f6hler\n                      : A. Finanzielle Interessen: F\u00f6rderung durch das Bundesministerium f\u00fcr Forschung und Bildung (BMBF), B\u2011FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) und NAPKON (Nationales Pandemie Kohorten Netz) des Netzwerks Universit\u00e4tsmedizin (NUM) des Landes Nordrhein-Westfalen und durch die Dr. Heinz Lux-Stiftung.\u00a0\u2013 Honorare f\u00fcr Vortr\u00e4ge von der Akademie f\u00fcr Infektionsmedizin e.\u202fV., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc, Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Akademie R\u00fcsselsheim, HELIOS Kliniken GmbH, Jazz Pharmaceuticals Germany GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Scilink Comunicaci\u00f3n Cient\u00edfica SC, streamedup! GmbH, Universit\u00e4tsklinikum und LMU M\u00fcnchen und VITIS GmbH.\u00a0\u2013 Beratungshonorare: Ambu GmbH, Gilead Sciences, infill healthcare communication GmbH, Mundipharma Research Limited, Noxxon N.V. und Pfizer Pharma. Teilnahme an Advisory Boards oder Data Review Committee von Ambu GmbH, Gilead Sciences, Mundipharma Research Limited und Pfizer Pharma; Ein angemeldetes Patent beim Deutschen Patent- und Markenamt (DE 10 2021 113 007.7). Andere nichtfinanzielle Interessen von Elsevier, Wiley und Taylor & Francis online au\u00dferhalb der eingereichten Arbeit. \u2013 B. Nichtfinanzielle Interessen: Oberarzt, Klinik I f\u00fcr Innere Medizin, Leitung Klinische Immunologie und Studienzentrum Klinische Immunologie | Universit\u00e4tsklinikum K\u00f6ln (A\u00f6R), Kerpener Str. 62, 50937K\u00f6ln | Mitgliedschaften: seit 03\/2016 Deutsche Gesellschaft f\u00fcr Infektiologie e.V. (DGI); seit 10\/2016 Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie e.\u202fV.(DGHO); seit 11\/2018 Deutschsprachige Mykologische Gesellschaft (DMykG); seit 02\/2019 Arbeitsgemeinschaft Infektionen in der H\u00e4matologie und Onkologie(AGIHO) der DGHO; 02\/2019 EHA SWG Infections in Hematology; seit 06\/2020 Mitglied Infectious Diseases Society of America (IDSA); seit 05\/2022 Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh); seit 11\/2023 Mitglied Deutsche Gesellschaft f\u00fcr Immunologie; seit 05\/2024 European Society for Immunodeficiencies; seit 12\/2024 Mitglied DGRh Rheumazentrum Aachen-K\u00f6ln-Bonn; seit 06\/2025 European Alliance of Associations for Rheumatology (EULAR); seit 06\/2025 EuropeanAlliance of Associations for Rheumatology (EULAR)\u00a0\u2013 Gene and Cell Therapy Study Group; seit 11\/2025 Mitglied Myositis Clinical Trial Consortium(MCTC).\n                      J. Rybniker\n                      : A. Finanzielle Interessen: J. Rybniker gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter Internist Uniklinik K\u00f6ln | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin, Deutsche Gesellschaft f\u00fcr Infektiologie, ESCMID. Wissenschaftliche Leitung.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}